Navigation Links
KemPharm's KP201 to be Featured at PAINWeek 2013
Date:8/28/2013

NORTH LIBERTY, Iowa, Aug. 28, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that Travis C. Mickle, Ph.D., President and CEO of KemPharm, will present a poster on KP201 at PAINWeek 2013, the nation's largest pain conference for frontline clinicians with an interest in pain management.  

The poster, entitled "KP201: A Novel Opioid Pain Therapy with Reduced Abuse Potential and Improved Safety," will be displayed on September 6, 2013 between 6:15 PM and 7:30 PM, PDT and will detail KP201's clinical studies and unique abuse-deterrent properties, which have been shown to significantly limit narcotic exposure upon intranasal administration and intravenous injection.  Additionally, the poster will highlight the potential for KP201 to prevent or reduce opioid-induced constipation (OIC).

Dr. Mickle commented, "Showcasing KP201 at PAINWeek 2013 provides an opportunity for clinicians with an interest in pain management to gain an understanding of the drug's advantages and its potential as a future treatment option for their patients.  We welcome the opportunity to present what we believe is very compelling data on KP201 that highlight not only its ability to treat pain but the added benefit of a reduction in abuse potential and opioid-induced constipation."

About KemPharmKemPharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach.  The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases.  KemPharm's lead clinical candidate, KP201, is in development for the treatment of acute, moderate to moderately severe pain with a new drug application (NDA) expected to be filed in the second quarter of 2014. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). KemPharm's pipeline is also highlighted by KP511, its hydromorphone prodrug for pain, and KP415, a prodrug of methylphenidate for the treatment of ADHD.  For more information on KemPharm, please visit the company's website at www.kempharm.com.For KemPharm, Inc:Media / Investor Contacts:Christal Mickle

319-665-2575

info@kempharm.comJason Rando / Joshua Drumm, Ph.D.

Tiberend Strategic Advisors, Inc.

212.827.0020

jrando@tiberend.com

jdrumm@tiberend.com  


'/>"/>
SOURCE KemPharm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. KemPharms KP201 Demonstrates Complete Metabolic Cleavage of Prodrug and Steady-State Pharmacokinetic Profiles for Hydrocodone, Hydromorphone and Acetaminophen
2. KemPharm, Inc. Receives Patent from the USPTO for Novel Pain Drug Candidate, KP201
3. KemPharm Advances KP201 Clinical and Commercial Program with Completion of Tablet Registration Activities
4. Millennium HealthCare Inc. Featured in Forbes
5. Actinium Pharmaceuticals Clinical Results Featured at a United Nations Forum
6. Mid-Atlantic Biotech Leaders Featured On BioSpace Map
7. B. Braun Smart Infusion Pump Technology to be Featured in Integrating the Healthcare Enterprise (IHE) Interoperability Demonstration at AAMI 2013
8. Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting
9. AVTs Customer Medbox, Inc. Featured in Bloomberg Businessweek
10. Zacks.com featured expert Kevin Matras highlights: Core Laboratories NV, Invesco Ltd., Medtronic, Inc., Willbros Group Inc. and WuXi PharmaTech Inc.
11. KaloBios Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Worldwide ... achieve significant growth as next generation systems provide ... use radiology for cancer surgery. New systems pinpoint ... overdosing that has been such a problem previously, ... delivered. Radiosurgery robots take cancer surgery far beyond ...
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... and competitive market to drive long-term market growth ... very common set of chronic disorders that affect ... disparate in terms of their symptoms and key ... by dysregulation of immune pathways and an inappropriate ...
Breaking Medicine Technology:
(Date:2/5/2016)... New York (PRWEB) , ... February 05, 2016 , ... ... use and find themselves having to wait longer to access the treadmills. It’s a ... New Year’s resolutions to lose weight and get in shape by joining gyms, starting ...
(Date:2/5/2016)... ... , ... At its annual meeting held last week, the American Parkinson Disease ... of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. , "We are pleased ... APDA President and CEO. “Pat has tirelessly served APDA since 2001 when he was ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Colorize ... on one drop zone to the next using Colorize's dynamic moving camera. Colorize is ... This package includes a 3D slideshow environment with 1 to 5 focus points per ...
(Date:2/5/2016)... ... 05, 2016 , ... On June 9-10, Las Vegas will ... education (CME) event presented by the Association for Comprehensive Care in Rare Diseases ... whose mission is to provide education, tools, and resources to primary care clinicians ...
(Date:2/5/2016)... Luis Obispo, CA (PRWEB) , ... February 05, 2016 , ... ... new changes that Medicare San Luis Obispo users can expect to see in 2016. ... , The two most significant changes will directly impact many San Luis Obispo seniors ...
Breaking Medicine News(10 mins):